CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022

Table 2 Outcomes of clinical trials of CAR-NK cells presented at ASH 2022

NCT number	Disease	Source	Target	Patient number	Preconditioning regimen	Cell dose (10⁸)	Combination	ORR/CR	GVHD	CRS/ICANS	Abstract Number	Reference
NCT05008575	AML	Umbilical cord-derived	CD33	10	FC	6, 12 and 18*	None	60%/60%	None	Grade 2 CRS: 1	3317	[11]
NCT05182073	MM	iPSCs	BCMA	6	FC	1 or 3	None	16.7%/0		None	2004	[12]
NCT05182073	MM	iPSCs	BCMA	3	FC	1	Daratumumab	66.7%/0		None	2004	[12]

^*Three patients received 3 rounds of CAR NK cells (6 × 10⁸, 1.2 × 10⁹ and 1.8 × 10⁹ cells) with an interval of 7 days. Three patients received one dose of 1.8 × 10⁹ CD33 CAR NK cells. In dose group three, four patients received 3 rounds of 1.8 × 10⁹ CD33 CAR NK cells with an interval of 7 days
AML acute myeloid leukemia, FC fludarabine and cyclophosphamide, MM multiple myeloma, iPSCs induced pluripotent stem cells, CAR chimeric antigen receptor, CRS cytokine release syndrome, ORR overall response rete, CR complete response, ICANS immune effector cell-associated neurotoxicity syndrome

ISSN: 1756-8722